Celsion reports net loss of $2.6M for second-quarter 2010
Celsion Corporation, a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma and in a Phase I/II trial for patients with recurrent chest wall breast cancer.
More... |
All times are GMT -7. The time now is 02:21 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021